The iLink™ Procedure
What is iLink™ corneal cross-linking?
iLink™ is the only FDA-approved corneal cross-linking procedure that slows or halts progressive keratoconus.
Early keratoconus diagnosis and treatment with iLink™
Watch this video for unique patient and doctor perspectives about progressive keratoconus and learn how the condition is treated with iLink™ corneal cross-linking.
The proprietary iLink™ procedure

The KXL System
- UVA irradiation: 30 minutes at 3 mW/cm²
- Laser alignment for patient positioning
- Wireless control for beam alignment in the X, Y, and Z axes
- Fully integrated stable delivery platform
- Touchscreen operation
- Self-calibration of UVA irradiation intensity
Photrexa® and Photrexa® Viscous
- Only FDA-approved bioactivated riboflavin ophthalmic solutions
- Manufactured using validated processes in a state-of-the-art drug manufacturing facility
- GMP-certified material
- Packaged and controlled under GMP standards
Left untreated, 1 in 5 patients with progressive keratoconus may require a corneal transplant. More than half of these patients could need multiple transplants within 20 years. 1, 2
[Pramanik] [Maharana]
Learn more about the iLink™ mechanism of action.
Get Started
View Our Digital Brochure
Explore additional information about iLink™ in our digital brochure and learn how the procedure is transforming the standard of care for progressive keratoconus.
See iLink™ in action
This step-by-step video provides an overview of how iLink™ corneal cross-linking is performed.
>95% of the commercially insured population has access to iLink™ corneal cross-linking.
Clinical study data
In clinical studies, cross-linking–treated eyes showed increasing improvement in Kmax from month 3 through month 12, while in untreated, sham eyes, Kmax demonstrated steepening.3
[Photrexa package insert 2016/p9/fig1]
Change From Baseline (Kmax)—Progressive Keratoconus Patients*3
[Photrexa package insert 2016/p9/fig1]
*Post-baseline missing data were imputed using last available Kmax value. For the sham study eyes that received cross-linking treatment after baseline, the last Kmax measurement recorded prior to receiving cross-linking treatment was used in the analysis for later time points. In Study 3, 4 patients in the cross-linking group had missing baseline Kmax value and were excluded from the analysis.
Learn more about iLink™ corneal cross-linking from the experts
Explore physician presentationsReferences
1. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638.
2. Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389.
3. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.